Session 1 Jan-2022 Q&A Follow-up Questions
apoB ApoA1 ratio predictive of CAD severity
Effect of bergamot on lipid profile in humans A systematic review
apoB should be the marker of atherogenic risk apoB for risk assessment 2016 editorial
apoB should be target for lipid therapy 2021
apoB or nonHDL in adolescence predicts CAD risk
hscTn a strong predictor of silent significant CAD editorial 102021
hscTnT and skeletal myopathies
hscTnT elevations may be due to OSA
Bergamot effect on lipoproteins in patients with metabolic syndrome
hscTn significantly enhances CV risk assessment in standard cholesterol risk estimate
hscTn can be elevated in CAD without ischemia
Bergamot reducing cholesterol and CV disease markers
Bergamot double blind trail lipid and visceral and waist improvement
hscTn a challenge in pts with CKD editorial
hscTnT genetic influence on levels and assoc with AF 112021
salt restriction improves BP and MACR in IR pts
MACR is related to endo dysfunciton and CKD in CAD
MACR can increase with exercise
MACR cut points men and women for CV risk
MACR can elevate with sickle cell and CKD
MACR influenced by processing delays and storage temp